Alcoholic Liver Disease Management

Primary Management Approach

Complete alcohol abstinence is the cornerstone of treatment for alcoholic liver disease (ALD) and represents the most important therapeutic goal to reduce the risk of complications and mortality, according to the European Association for the Study of the Liver 1, 2, 3
Psychiatric consultation is recommended for evaluation, treatment, and long-term planning of alcohol abstinence, as suggested by the American Association for the Study of Liver Diseases 4
Baclofen is useful and safe as an anti-craving medication in patients with advanced liver disease, as reported by the European Association for the Study of the Liver 1
Brief interventions using the FRAMES model (Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy) should be implemented to encourage abstinence, according to the American College of Physicians 3

Aggressive nutritional therapy rich in calories and proteins is essential for patients with alcoholic liver disease, as recommended by the European Association for the Study of the Liver 1, 2
Thiamine supplementation (100-300 mg/day) should be given to all patients with alcohol withdrawal syndrome and maintained for 2-3 months, as suggested by the American Association for the Study of Liver Diseases 4
In severe cases of malnutrition, consultation with a dietitian is recommended, according to the European Association for the Study of the Liver 2

Identify and manage cofactors including obesity, insulin resistance, malnutrition, cigarette smoking, iron overload, and viral hepatitis, as recommended by the European Association for the Study of the Liver 2, 5
Screen for alcohol-induced damage to other organs including heart (alcoholic cardiomyopathy), kidney (IgA-induced nephropathy), nervous system, and pancreas, according to the American Association for the Study of Liver Diseases 2, 3

Inpatient treatment is recommended for cases with serious complications such as alcohol withdrawal delirium or seizures, as suggested by the American Association for the Study of Liver Diseases 4
Benzodiazepines are the first-line treatment for AWS, according to the American College of Physicians 4
Long-acting benzodiazepines (chlordiazepoxide, diazepam) are recommended for prevention of seizures, as reported by the American Association for the Study of Liver Diseases 4
Lorazepam (6-12 mg/day) is preferred for patients with severe AWS, advanced age, head trauma, liver failure, respiratory failure, other serious medical comorbidities, or obesity, according to the American Association for the Study of Liver Diseases 4

Hepatic encephalopathy is associated with the highest mortality among complications of decompensated cirrhosis, as reported by the European Association for the Study of the Liver 2, 3
Standard treatment includes lactulose and rifaximin according to cirrhosis guidelines, as recommended by the American Association for the Study of Liver Diseases 3
In patients with impaired cognitive function, rule out alcoholic dementia, withdrawal syndrome, and Wernicke's encephalopathy, according to the European Association for the Study of the Liver 2
Primary and secondary prophylaxis of variceal bleeding should follow standard cirrhosis guidelines, as recommended by the European Association for the Study of the Liver 2, 5
Patients with alcoholic cirrhosis have approximately 6% risk of variceal bleeding in the first year after diagnosis, as reported by the European Association for the Study of the Liver 2

For severe alcoholic hepatitis with Maddrey Discriminant Factor ≥32, pentoxifylline and/or corticosteroids should be offered unless contraindicated, as suggested by the European Association for the Study of the Liver 6
N-acetylcysteine may be useful in patients with severe ASH receiving corticosteroids, according to the European Association for the Study of the Liver 6
Early non-response to steroids should be identified and rules for cessation of therapy should be considered, as reported by the European Association for the Study of the Liver 6

Liver transplantation is the most effective therapeutic option for end-stage liver disease, as recommended by the American Association for the Study of Liver Diseases 3
The Model for End-Stage Liver Disease (MELD) score should be used to establish prognosis and prioritize for liver transplantation, according to the European Association for the Study of the Liver 2, 3
Most programs require a 6-month period of abstinence prior to evaluation for transplantation, as reported by the European Association for the Study of the Liver 7, 8
Graft and patient survival rates among alcoholics after liver transplantation are similar to those seen after transplantation for other etiologies of liver disease, according to the European Association for the Study of the Liver 7